Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Matinas BioPharma ( (MTNB) ) just unveiled an update.
On April 30, 2025, Matinas BioPharma Holdings, Inc. amended its bylaws to reduce the quorum requirement for stockholder meetings to one-third of the voting power, aiming to facilitate the holding of such meetings. Additionally, the company amended employment agreements for key executives Jerome D. Jabbour and Keith Kucinski, introducing cash retention bonuses in the event of a change in control by March 31, 2026. The company also announced June 23, 2025, as the date for its 2025 annual stockholders meeting, with a record date set for May 1, 2025, and provided deadlines for stockholder proposals and board nominations.
Spark’s Take on MTNB Stock
According to Spark, TipRanks’ AI Analyst, MTNB is a Neutral.
The overall score reflects significant financial challenges due to declining revenues and persistent losses. Positive technical indicators provide some optimism, while valuation remains unattractive with a negative P/E ratio and no dividend yield. The recent board appointments may offer strategic improvements, but substantial progress is needed to improve financial health and stock performance.
To see Spark’s full report on MTNB stock, click here.
More about Matinas BioPharma
YTD Price Performance: 5.08%
Average Trading Volume: 120,547
Technical Sentiment Signal: Buy
Current Market Cap: $3.15M
Find detailed analytics on MTNB stock on TipRanks’ Stock Analysis page.